Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -35.02% is 59% above its 5-year average of -85.01%, near the high end of its 5-year range (-190.23%–27.75%).
As of the fiscal period ended Tuesday, June 30, 2026. 28.52% above its 12-month average of -48.99%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -35.02%.
RETURN ON EQUITY (ROE)
-35.02%
RETURN ON EQUITY (ROE) AVG TTM
-48.99%
RETURN ON EQUITY (ROE) AVG 3Y
-90.18%
RETURN ON EQUITY (ROE) AVG 5Y
-85.01%
RETURN ON EQUITY (ROE) AVG 10Y
-87.57%
RETURN ON EQUITY (ROE) AVG 15Y
-70.26%
RETURN ON EQUITY (ROE) AVG 20Y
-60.08%
CURRENT VS TTM AVG
+28.52%
CURRENT VS 3Y AVG
+61.17%
CURRENT VS 5Y AVG
+58.81%
CURRENT VS 10Y AVG
+60.01%
CURRENT VS 15Y AVG
+50.16%
CURRENT VS 20Y AVG
+41.71%
SECTOR MEDIAN · HEALTHCARE
-40.21%
median of 609 covered companies
CURRENT VS SECTOR MEDIAN
+12.91%
vs the sector median at left
Lexicon Pharmaceuticals, Inc.
Market Cap
$788.45M
Return on Equity (ROE)
-35.02%
TTM Avg
-48.99%
3Y Avg
-90.18%
5Y Avg
-85.01%
Market Cap
$789.07M
Return on Equity (ROE)
-31.97%
TTM Avg
-50.13%
3Y Avg
-87.97%
5Y Avg
-79.93%
Market Cap
$799.38M
Return on Equity (ROE)
-13.30%
TTM Avg
11.91%
3Y Avg
154.09%
5Y Avg
54.89%
Market Cap
$796.23M
Return on Equity (ROE)
-16.56%
TTM Avg
0.55%
3Y Avg
-10.56%
5Y Avg
-13.37%
Market Cap
$778.78M
Return on Equity (ROE)
2.54%
TTM Avg
1.18%
3Y Avg
-43.07%
5Y Avg
-28.50%
Market Cap
$776.26M
Return on Equity (ROE)
-40.21%
TTM Avg
-52.14%
3Y Avg
-52.14%
5Y Avg
-52.14%
Market Cap
$805.59M
Return on Equity (ROE)
12.32%
TTM Avg
19.75%
3Y Avg
23.44%
5Y Avg
27.16%
Market Cap
$807.84M
Return on Equity (ROE)
N/A
TTM Avg
-5137.85%
3Y Avg
-2593.82%
5Y Avg
-1731.57%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexicon Pharmaceuticals, Inc. (LXRX) | $788.45M | -35.02% | -48.99% | -90.18% | -85.01% |
| Geron Corporation (GERN)vs › | $789.07M | -31.97% | -50.13% | -87.97% | -79.93% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $799.38M | -13.30% | 11.91% | 154.09% | 54.89% |
| AdaptHealth Corp. (AHCO)vs › | $796.23M | -16.56% | 0.55% | -10.56% | -13.37% |
| Mesa Laboratories, Inc. (MLAB)vs › | $778.78M | 2.54% | 1.18% | -43.07% | -28.50% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $776.26M | -40.21% | -52.14% | -52.14% | -52.14% |
| Apnimed, Inc. (APMD)vs › | $804.23M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $805.59M | 12.32% | 19.75% | 23.44% | 27.16% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $807.84M | N/A | -5137.85% | -2593.82% | -1731.57% |
| Design Therapeutics, Inc. (DSGN)vs › | $767.14M | -35.07% | -26.66% | -24.19% | -5.48% |
ROE
-35.0%
ROA
-24.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -35.02% |
| 2026-03-31 | -12.86% |
| 2025-12-31 | -46.81% |
| 2025-09-30 | -57.07% |
| 2025-06-30 | -93.19% |
| 2025-03-31 | -144.11% |
| 2024-12-31 | -137.31% |
| 2024-09-30 | -121.22% |
| 2024-06-30 | -84.22% |
| 2024-03-31 | -67.01% |
| 2023-12-31 | -190.23% |
| 2023-09-30 | -113.15% |
| 2023-06-30 | -70.14% |
| 2023-03-31 | -125.39% |
| 2022-12-31 | -87.04% |
| 2022-09-30 | -67.40% |
| 2022-06-30 | -136.66% |
| 2022-03-31 | -97.39% |
| 2021-12-31 | -77.26% |
| 2021-09-30 | -49.52% |
| 2021-06-30 | 27.75% |
| 2021-03-31 | -8.47% |
| 2020-12-31 | -37.46% |
| 2020-09-30 | -118.92% |
| 2020-03-31 | 155.76% |
| 2019-12-31 | 111.13% |
| 2019-09-30 | 99.87% |
| 2018-03-31 | -520.10% |
| 2017-12-31 | -247.69% |
| 2017-09-30 | -169.81% |
| 2017-06-30 | -130.17% |
| 2017-03-31 | -105.08% |
| 2016-12-31 | -89.85% |
| 2016-09-30 | -12.02% |
| 2016-06-30 | -9.91% |
| 2016-03-31 | -4.54% |
| 2015-12-31 | -1.64% |
| 2015-09-30 | -47.67% |
| 2015-06-30 | -43.02% |
| 2015-03-31 | -37.86% |
| 2014-12-31 | -35.31% |
| 2014-09-30 | -147.48% |
| 2014-06-30 | -90.80% |
| 2014-03-31 | -77.42% |
| 2013-09-30 | -60.09% |
| 2013-06-30 | -50.89% |
| 2013-03-31 | -43.89% |
| 2012-12-31 | -41.33% |
| 2012-09-30 | -47.15% |
| 2012-06-30 | -47.26% |
| 2012-03-31 | -43.30% |
| 2011-12-31 | -39.05% |
| 2011-09-30 | -62.17% |
| 2011-06-30 | -54.99% |
| 2011-03-31 | -48.03% |
| 2010-12-31 | -41.20% |
| 2010-09-30 | -37.49% |
| 2010-06-30 | -31.32% |
| 2010-03-31 | -28.46% |
| 2009-12-31 | -52.66% |
| 2009-09-30 | -61.55% |
| 2009-06-30 | -57.09% |
| 2009-03-31 | -48.53% |
| 2008-12-31 | -44.07% |
| 2008-09-30 | -39.33% |
| 2008-06-30 | -31.67% |
| 2008-03-31 | -26.39% |
| 2007-12-31 | -22.94% |
| 2007-09-30 | -22.77% |
| 2007-06-30 | -73.92% |
| 2007-03-31 | -90.42% |
| 2006-12-31 | -63.52% |
| 2006-09-30 | -63.26% |
| 2006-06-30 | -58.10% |
| 2006-03-31 | -44.04% |
| 2005-12-31 | -42.32% |
| 2005-09-30 | -53.56% |
| 2005-06-30 | -45.82% |
| 2005-03-31 | -41.49% |
| 2004-12-31 | -38.79% |
| 2004-09-30 | -50.42% |
| 2004-06-30 | -45.26% |
| 2004-03-31 | -40.92% |
| 2003-12-31 | -38.62% |
| 2003-09-30 | -35.40% |
| 2003-06-30 | -46.63% |
